<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03175835</url>
  </required_header>
  <id_info>
    <org_study_id>148DDI16023</org_study_id>
    <nct_id>NCT03175835</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Drug Interaction Between CKD-519 and Rosuvastatin in Healthy Male Subjects</brief_title>
  <official_title>An Open-label, Multiple Dose, Fixed-sequence, 3-period Study to Evaluate the Drug Interaction Between CKD-519 and Rosuvastatin in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the drug interaction between CKD-519 and&#xD;
      rosuvastatin in healthy male subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open-label, multiple dose, fixed-sequence, 3-period study to evaluate the drug interaction&#xD;
      between CKD-519 and rosuvastatin in healthy male subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 8, 2017</start_date>
  <completion_date type="Actual">June 19, 2017</completion_date>
  <primary_completion_date type="Actual">June 19, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (Area under the plasma concentration versus time curve (AUCτ))</measure>
    <time_frame>0(predose)~24 hours at Day1, Day3, Day4, Day5, Day9, Day12, Day15, Day17, Day18, Day19, Day22, Day24, Day25, Day26</time_frame>
    <description>At steady state after multiple administration of CKD-519, Rosuvastatin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Peak plasma Concentration (Cmax,ss))</measure>
    <time_frame>0(predose)~24 hours at Day1, Day3, Day4, Day5, Day9, Day12, Day15, Day17, Day18, Day19, Day22, Day24, Day25, Day26</time_frame>
    <description>At steady state after multiple administration of CKD-519, Rosuvastatin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Minimum plasma Concentration (Cmin,ss))</measure>
    <time_frame>0(predose)~24 hours at Day1, Day3, Day4, Day5, Day9, Day12, Day15, Day17, Day18, Day19, Day22, Day24, Day25, Day26</time_frame>
    <description>At steady state after multiple administration of CKD-519, Rosuvastatin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Time to maximum plasma concentration (Tmax,ss))</measure>
    <time_frame>0(predose)~24 hours at Day1, Day3, Day4, Day5, Day9, Day12, Day15, Day17, Day18, Day19, Day22, Day24, Day25, Day26</time_frame>
    <description>At steady state after multiple administration of CKD-519, Rosuvastatin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (t1/2)</measure>
    <time_frame>0(predose)~24 hours at Day1, Day3, Day4, Day5, Day9, Day12, Day15, Day17, Day18, Day19, Day22, Day24, Day25, Day26</time_frame>
    <description>At steady state after multiple administration of CKD-519, Rosuvastatin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (CETP activity)</measure>
    <time_frame>0(predose)~24 hours at Day9, Day12, Day15, Day17, Day18, Day19, Day22, Day24, Day25, Day26</time_frame>
    <description>At steady state after multiple administration of CKD-519, Rosuvastatin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (CETP Concentration)</measure>
    <time_frame>0(predose)~24 hours at Day9, Day19, Day22, Day26</time_frame>
    <description>At steady state after multiple administration of CKD-519, Rosuvastatin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (Lipid profiles)</measure>
    <time_frame>simultaneous with laboratory test at Day1, Day6, Day9, Day20, Day22, Day27</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>Rosuvastatin 20 mg &amp; CKD-519 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Treatment A(Rosuvastatin 20 mg(20 mg X 1 tablet))&#xD;
Period 2: Treatment B(CKD-519 200 mg(100 mg X 2 tablets))&#xD;
Period 3: Treatment C(Rosuvastatin 20 mg(20 mg X 1 tablet), CKD-519 200 mg(100 mg X 2 tablets))</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin 20 mg</intervention_name>
    <description>Treatment A: Rosuvastatin 20 mg(20 mg X 1 tablet) for Day1~Day5</description>
    <arm_group_label>Rosuvastatin 20 mg &amp; CKD-519 200 mg</arm_group_label>
    <other_name>Rosuvastatin 20 mg(20 mg X 1 tablet)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-519 200 mg</intervention_name>
    <description>Treatment B: CKD-519 200 mg(100 mg X 2 tablets) for Day9~Day21</description>
    <arm_group_label>Rosuvastatin 20 mg &amp; CKD-519 200 mg</arm_group_label>
    <other_name>CKD-519 200 mg(100 mg X 2 tablets)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin 20 mg &amp; CKD-519 200 mg</intervention_name>
    <description>Treatment C: Rosuvastatin 20 mg(20 mg X 1 tablet), CKD-519 200 mg(100 mg X 2 tablets) for Day22~Day26</description>
    <arm_group_label>Rosuvastatin 20 mg &amp; CKD-519 200 mg</arm_group_label>
    <other_name>Rosuvastatin 20 mg(20 mgX1 tablet), CKD-519 200 mg(100 mgX2 tablets)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy volunteers aged between ≥ 20 and ≤ 45 years old&#xD;
&#xD;
          2. Weight ≥ 50kg, with calculated body mass index(BMI) of ≥ 18 and ≤ 29.9kg/m²&#xD;
&#xD;
          3. Subjects to consents to use effective birth controls for at least 2 months following&#xD;
             the last dose&#xD;
&#xD;
          4. Subject is informed of the investigational nature of this study and voluntarily agrees&#xD;
             to participate in this study and comply with the relevant instructions in written&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History or presence of clinically significant and active cardiovascular, respiratory,&#xD;
             hepatobiliary, renal, endocrine, hematological, gastrointestinal, neurologic, immune,&#xD;
             dermatologic or psychiatric disorder&#xD;
&#xD;
          2. With symptoms indicating acute illness within 28 days prior to the first&#xD;
             Investigational Product administration&#xD;
&#xD;
          3. Any medical history that may affect drug absorption, distribution, metabolism and&#xD;
             excretion&#xD;
&#xD;
          4. Any hypersensitivity reaction or clinically significant hypersensitivity reaction in&#xD;
             the history of statin-related medication or Cholesteryl Ester Transfer Protein(CETP)&#xD;
             inhibitor or other drugs(aspirin, antibiotics)&#xD;
&#xD;
          5. Continuous cryptogenic elevation of serum transaminase or active liver disease&#xD;
             including elevation of serum transaminase &gt; 3 fold upper normal limit(UNL)&#xD;
&#xD;
          6. Severe renal failure(creatinin clearance &lt; 30 ml/min)&#xD;
&#xD;
          7. Hypothyroidism or clinically significant test result&#xD;
&#xD;
          8. Galactose intolerance, Lapp lactose intolerance, glucose-galactose malabsorption or&#xD;
             genetic disorders&#xD;
&#xD;
          9. Any clinically significant chronic medical illness&#xD;
&#xD;
         10. Any clinically significant hypotension or hypertension (systolic &lt; 100 mmHg/diastolic&#xD;
             &lt; 60 mmHg or systolic &gt; 140 mmHg /diastolic &gt; 90 mmHg)&#xD;
&#xD;
         11. Corrected QT interval(QTc) &gt;450msec on 12-lead ECG&#xD;
&#xD;
         12. Positive blood tests for hemoglobins(HBs) Ag, anti-hepatitis C virus(HCV) Ab, anti-HIV&#xD;
             Ab, or venereal disease research laboratory(VDRL)&#xD;
&#xD;
         13. Creatine phosphokinase(CPK) ≥ 5 fold of upper normal limit(UNL)&#xD;
&#xD;
         14. Use of any prescription drugs within 14 days prior to study drug administration&#xD;
&#xD;
         15. Use of any other drugs, including over-the-counter medications and herbal preparations&#xD;
             within 7 days prior to study drug administration&#xD;
&#xD;
         16. History of clinically significant allergic reaction (However, mild allergic rhinitis&#xD;
             or allergic dermatitis which do not require any treatment may be allowed)&#xD;
&#xD;
         17. Inability to take normal hospital diet&#xD;
&#xD;
         18. Donation of blood within 60 days prior to study drug administration or plasma to a&#xD;
             blood bank within 20 days prior to study drug administration&#xD;
&#xD;
         19. Blood transfusion within 30 days prior to study drug administration&#xD;
&#xD;
         20. Exposure to any investigational drug or placebo within 90 days prior to the first&#xD;
             Investigational Product(IP) administration&#xD;
&#xD;
         21. Subjects taking any drugs to induce or inhibit drug metabolizing enzymes including&#xD;
             barbiturates within 30 days prior to the first Investigational Product(IP)&#xD;
             administration&#xD;
&#xD;
         22. Subjects with excessive caffeine intake (more than 5 cups/day), heavy smoking (more&#xD;
             than 10 cigarettes/day), regular alcohol intake (more than 210 g/week)&#xD;
&#xD;
         23. Subjects having been deemed inappropriate for the trial as determined by the&#xD;
             investigator&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>May 18, 2017</study_first_submitted>
  <study_first_submitted_qc>June 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2017</study_first_posted>
  <last_update_submitted>July 5, 2017</last_update_submitted>
  <last_update_submitted_qc>July 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dyslipidemia</keyword>
  <keyword>CKD-519</keyword>
  <keyword>Rosuvastatin</keyword>
  <keyword>Drug-Drug Interaction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

